Silvia Cacciatore

Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis

Hagop M. Kantarjian, Timothy P. Hughes, Richard A. Larson et al. · Leukemia · 2021 · 351 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +7

<scp>l</scp>‐DOPA activates ERK signaling and phosphorylates histone H3 in the striatonigral medium spiny neurons of hemiparkinsonian mice

Emanuela Santini, Cristina Alcacer, Silvia Cacciatore et al. · Journal of Neurochemistry · 2008 · 185 citations

Life Sciences, Neurobiology, Neuroscience +17

Asciminib, a First-in-Class STAMP Inhibitor, Provides Durable Molecular Response in Patients (pts) with Chronic Myeloid Leukemia (CML) Harboring the T315I Mutation: Primary Efficacy and Safety Results from a Phase 1 Trial

Jörge E. Cortes, Timothy P. Hughes, Michael J. Mauro et al. · Blood · 2020 · 53 citations

Medicine, Oncology, Pharmacology +9

Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results

Jörge E. Cortes, Koji Sasaki, Dong‐Wook Kim et al. · Leukemia · 2024 · 51 citations · Full text

Medicine, Oncology, Pharmacology +9

Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results

Michael J. Mauro, Timothy P. Hughes, Dong‐Wook Kim et al. · Leukemia · 2023 · 47 citations · Full text

Medicine, Oncology, Pharmacology +10